(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of 0.46% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Viatris's revenue in 2025 is $14,115,700,000.On average, 3 Wall Street analysts forecast VTRS's revenue for 2025 to be $16,126,859,742,016, with the lowest VTRS revenue forecast at $15,993,783,599,824, and the highest VTRS revenue forecast at $16,294,613,584,754. On average, 3 Wall Street analysts forecast VTRS's revenue for 2026 to be $16,439,511,670,314, with the lowest VTRS revenue forecast at $16,297,843,050,546, and the highest VTRS revenue forecast at $16,589,124,542,755.
In 2027, VTRS is forecast to generate $16,669,203,635,671 in revenue, with the lowest revenue forecast at $16,611,812,414,347 and the highest revenue forecast at $16,776,993,177,300.